



Name	Sung Wook Hwang
Affiliation	University of Ulsan College of Medicine, Asan Medical Center
Country	Korea
Major Field	Gastroenterology, Inflammatory Bowel Disease

Educational Background
Ph.D. of medicine, March 2016 – February 2019 Graduate school of medicine, University of Ulsan College of Medicine, Ulsan, Korea
Master of medicine, March 2009 to February 2014 Graduate school of medicine, Seoul National University, Seoul, Korea
Medical Student, March 1998 to February 2005 College of Medicine, Seoul National University, Seoul, Korea

Professional Experience
Associate Professor, March 2022 – Present Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
Assistant Professor, March 2017 – February 2022 Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
Visiting scholar, July 2019 to June 2021 Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA
Clinical Assistant Professor, March 2015 to February 2017 Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
Fellowship, May 2013 to February 2015 Division of gastroenterology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
Residency, March 2006 to February 2010 Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
Internship, March 2005 to February 2006 Seoul National University Hospital, Seoul, Korea



Main Scientific Publications

Real-World Experience of Switching from Intravenous to Subcutaneous Vedolizumab in Korean Patients with Inflammatory Bowel Disease. Gut Liver. 2025

Comparative efficacy of subcutaneous infliximab switching in remission and non-remission patients with inflammatory bowel disease after intravenous maintenance: 1-year outcome from a multicentre cohort study. Therap Adv Gastroenterol. 2025

Temporal trends in obesity and its prognostic impact in Korean patients with inflammatory bowel disease. J Gastroenterol. 2025

Fecal calprotectin from ileostomy output in patients with Crohn's disease. BMC Gastroenterol. 2025

CD8+ cell dominance in immune checkpoint inhibitor-induced colitis and its heterogeneity across endoscopic features. Therap Adv Gastroenterol. 2024

Characteristics, clinical outcomes, and prognostic factors of colorectal cancer in patients with Crohn's disease: American versus Korean tertiary referral center perspectives. Therap Adv Gastroenterol. 2024

Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events. Clin Endosc. 2024

Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure. Gut Liver. 2024

Fecal Calprotectin in Patients with Crohn's Disease: A Study Based on the History of Bowel Resection and Location of Disease. Diagnostics (Basel). 2024